HC Wainwright reissued their buy rating on shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) in a research report sent to investors on Tuesday morning. HC Wainwright currently has a $11.00 price objective on the biopharmaceutical company’s stock.

Several other analysts have also issued reports on the stock. Chardan Capital lifted their target price on shares of Vascular Biogenics from $20.00 to $25.00 and gave the company a buy rating in a research report on Monday, November 6th. Zacks Investment Research upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research report on Wednesday, October 18th. Finally, ValuEngine upgraded shares of Vascular Biogenics from a sell rating to a hold rating in a research report on Wednesday, September 20th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $16.00.

Shares of Vascular Biogenics (NASDAQ VBLT) opened at $7.00 on Tuesday. Vascular Biogenics has a 52-week low of $3.90 and a 52-week high of $9.05.

COPYRIGHT VIOLATION WARNING: “HC Wainwright Reaffirms Buy Rating for Vascular Biogenics Ltd. (VBLT)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The original version of this news story can be accessed at https://www.watchlistnews.com/hc-wainwright-reaffirms-buy-rating-for-vascular-biogenics-ltd-vblt/1723830.html.

A hedge fund recently bought a new stake in Vascular Biogenics stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 22,100 shares of the biopharmaceutical company’s stock, valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.08% of Vascular Biogenics at the end of the most recent quarter. 7.26% of the stock is owned by hedge funds and other institutional investors.

About Vascular Biogenics

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.

Receive News & Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.